Infliximab--recommandations pratiques pour te traitement de la maladie de Crohn. [Infliximab--practical guidelines for the treatment of Crohn's disease]

Details

Serval ID
serval:BIB_1B9F864F0446
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Infliximab--recommandations pratiques pour te traitement de la maladie de Crohn. [Infliximab--practical guidelines for the treatment of Crohn's disease]
Journal
Revue Médicale Suisse
Author(s)
Bauerfeind  P., Beglinger  C., Beltinger  J., Braegger  C., Eigenmann  F., Fried  M., Guyot  J., Hurlimann  R., Michetti  P., Seibold  F., Straumann  A.
ISSN
1660-9379 (Print)
Publication state
Published
Issued date
07/2006
Volume
2
Number
74
Pages
1807-15
Notes
English Abstract
Journal Article
Review --- Old month value: Jul 26
Abstract
Infliximab is a monoclonal chimeric antibody, with high affinity and specificity for tumour necrosis factor alpha (TNFalpha) that plays a central role in the pathogenesis of immune mediated inflammatory disorders including Crohn's disease and ulcerative colitis. Globally over 600000 patients have been treated with infliximab to date. This global experience led to a better definition of the overall safety and efficacy profile of this medication. The goal of the present recommendations is to provide practical information to physicians involved in the care of patients with inflammatory bowel disease.
Keywords
Antibodies, Monoclonal/*therapeutic use Crohn Disease/*drug therapy Gastrointestinal Agents/*therapeutic use Humans
Pubmed
Create date
25/01/2008 16:02
Last modification date
20/08/2019 12:52
Usage data